Xiaoling Xuei

Has grant

Research professor

Indiana University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Close

Collaborative Studies on the Genetics of Alcoholism

Open Date:

Close Date:

Articles (22)

Lipid metabolism and the serine, one-carbon, glycine (SOG) and methionine pathways are independently and significantly correlated with estrogen receptor–negative breast cancer (ERneg BC). Here, we propose a link between lipid metabolism and ERneg BC through phosphoglycerate dehydrogenase (PHGDH), the rate-limiting enzyme in the de novo serine pathway. We demonstrate that the metabolism of the paradigmatic medium-chain fatty acid octanoic acid leads to a metabolic shift toward the SOG and methionine pathways. PHGDH plays a role in both the forward direction, contributing to the production of S-adenosylmethionine, and the reverse direction, generating the oncometabolite 2-hydroxyglutarate, leading to epigenomic reprogramming and phenotypic plasticity. The methionine cycle is closely linked to the transsulfuration pathway. Consequently, we observe that the shift increases the antioxidant glutathione, which mitigates reactive oxygen species (ROS), enabling survival of a subset of cells that have undergone DNA damage. These metabolic changes contribute to several hallmarks of cancer.

Year:

2025

Juvenile myelomonocytic leukemia (JMML) is a hematologic malignancy of young children caused by mutations that increase Ras signaling output. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment, but patients with relapsed or refractory (advanced) disease have dismal outcomes. This phase II trial evaluated the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in patients with advanced JMML. Ten infants and children were enrolled, and the objective response rate was 50%. Four patients with refractory disease proceeded to HSCT after receiving trametinib. Three additional patients completed all 12 cycles permitted on study and continue to receive off-protocol trametinib without HSCT. The remaining three patients had progressive disease with two demonstrating molecular evolution by the end of cycle 2. Transcriptomic and proteomic analyses provided novel insights into the mechanisms of response and resistance to trametinib in JMML. ClinicalTrials.gov Identifier: NCT03190915. Significance: Trametinib was safe and effective in young children with relapsed or refractory JMML, a lethal disease with poor survival rates. Seven of 10 patients completed the maximum 12 cycles of therapy or used trametinib as a bridge to HSCT and are alive with a median follow-up of 24 months. See related commentary by Ben-Crentsil and Padron, p. 1574

Year:

2024

Juvenile myelomonocytic leukemia (JMML) is a hematologic malignancy of young children caused by mutations that increase Ras signaling output. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment, but patients with relapsed or refractory (advanced) disease have dismal outcomes. This phase II trial evaluated the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in patients with advanced JMML. Ten infants and children were enrolled, and the objective response rate was 50%. Four patients with refractory disease proceeded to HSCT after receiving trametinib. Three additional patients completed all 12 cycles permitted on study and continue to receive off-protocol trametinib without HSCT. The remaining three patients had progressive disease with two demonstrating molecular evolution by the end of cycle 2. Transcriptomic and proteomic analyses provided novel insights into the mechanisms of response and resistance to trametinib in JMML. ClinicalTrials.gov Identifier: NCT03190915. Significance: Trametinib was safe and effective in young children with relapsed or refractory JMML, a lethal disease with poor survival rates. Seven of 10 patients completed the maximum 12 cycles of therapy or used trametinib as a bridge to HSCT and are alive with a median follow-up of 24 months. See related commentary by Ben-Crentsil and Padron, p. 1574

Year:

2024

Immortalized BRCA1- or BRCA2-mutant cells display elevated NFκB activity. A, PIK3CA H1047R distinctly influences differentiation properties of immortalized BRCA1 and BRCA2 mutation carriers. Vector control or PIK3CA H1047R -expressing breast epithelial cell lines from non-carriers (KTB34 and KTB39) and BRCA1 or BRCA2 mutation carriers were stained with indicated antibodies and characterized by flow cytometry ( n = 3). Representative data are shown. PIK3CA H1047R robustly increased EpCAM expression and increased differentiated phenotype of BRCA1-mutant cells. CD49f + /EpCAM + cells increased from 12% to 36% whereas CD49f + /EpCAM − cells decreased from 80% to 34% upon PIK3CA H1047R overexpression. B, BRCA1 mutant cells display elevated phosphorylation of p65, a NFκB subunit, which indirectly suggests activation of NFκB. Expression levels of PIK3CA in cells transduced with PIK3CA-mutant virus are shown. Regular growth media condition had to be used to detect PIK3CA-mutant overexpression because of robust induction of endogenous PIK3CA upon serum starvation. An antibody that preferentially recognizes PIK3CA H1047R mutant was used in the Western blot analysis. The same extract was used to measure pAKT(S473) and AKT to ensure that PIK3CA H1047R is functional in transduced cells. C, Approximately 30% of breast cancers in BRCA1 or BRCA2 mutation carriers carry PIK3CA mutations. Data were generated using cBioportal ( 54 ). D, Immortalized BRCA1 or BRCA2 mutant cells but not cells from non-carriers are sensitive to DMAPT. PIK3CA H1047R -overexpressing cells, irrespective of BRCA mutation status, were sensitive to DMAPT (statistical test used—one-way ANOVA). E, Immortalized cell lines from BRCA1 or BRCA2 mutation carriers express higher levels of MIR205HG (statistical test used—unpaired t test). Note that PIK3CA H1047R , which robustly induced differentiation of BRCA1-mutant cells, reduced MIR205HG levels in these cells. P values, *

Year:

2024

Expression levels of previously described BL-enriched genes as well as those described to be enriched in breast epithelial cells of BRCA1 mutation carriers. A, Expression patterns of specific genes in cells from BRCA1 mutation carrier compared with non-carriers. Alveolar progenitor (AP) cell–enriched and BL cell–enriched genes are indicated. KIT expression is shown to mark LASP cells. Note a unique subpopulation within LASP cells that express higher levels of ALDH1A3 in BRCA1 mutation carriers. CALML5 and FAM3B are AP-enriched whereas SCGB2A2 and FXYD5 are BL-enriched genes. B, Expression patterns of specific genes in cells from BRCA2 mutation carriers compared with non-carriers.

Year:

2024

Comparison of breast epithelial cells of BRCA1 and BRCA2 mutation carriers with that of non-carriers. Breast epithelial cells were subclassified into BM, LASP, and LHS cells based on CD49f and EpCAM expression status as described previously ( 10 ). A, Side-by-side comparison of breast epithelial cells of BRCA1 mutation carriers with that of non-carriers. A distinct cluster of LASP cells is present only in non-carriers (indicated by an oval shape). B, Side-by-side comparison of breast epithelial cells of BRCA2 with that of non-carriers. Similar to BRCA1, a distinct cluster of LASP cells is present only in non-carriers. C, Side-by-side comparison of breast epithelial cells from BRCA1 mutation carriers with that of BRCA2 mutation carriers. D, Distribution pattern of BM, LASP, and LHS cells in non-carrier, BRCA1 and BRCA2 mutation carriers. E, Heat map showing top 10 genes highly expressed in cluster missing in BRCA1 and BRCA2 mutation carriers compared with other clusters.

Year:

2024

Overlay of BRCA1 and BRCA2 single-cell map over the single-cell map of breast tissues from non-carriers. A, Overlay of BRCA1 carrier-derived single-cell atlas with that of non–carrier-derived atlas. Non–carrier-derived atlas has been described previously ( 10 ). Few minor clusters found in non-carrier atlas show limited overlap with BRCA1 mutation carrier-derived clusters (clusters 18, 20, and 21, oval in the center). All three are epithelial cell clusters. B, Overlay of BRCA2-derived single-cell atlas with non–carrier-derived atlas. Clusters 15 and 20, both epithelial clusters, are underrepresented in BRCA2 carriers. C, Overlay of BRCA1 carrier-derived single-cell atlas with that of BRCA2 carrier-derived single-cell atlas. A minor cluster (cluster 19) is underrepresented in BRCA1 compared with BRCA2 carrier-derived single-cell atlas.

Year:

2024

Single-cell atlas of breast tissues of BRCA1 and BRCA2 mutation carriers compared with breast tissues of non-carriers. A, tSNE plots showing single-cell map of the breast tissues from the right and left breast tissues of a 45-year-old BRCA1 mutation carrier. B, tSNE plots showing single-cell map of the breast tissues from 67 years old (left) and 39 years old (right) BRCA2 mutation carriers. C, UMAP showing integrated data from all samples sequenced. D, UMAP of individual sample overlay with cluster numbers.

Year:

2024

Single-cell transcriptomics studies have begun to identify breast epithelial cell and stromal cell specific transcriptome differences between BRCA1/2 mutation carriers and non-carriers. We generated a single-cell transcriptome atlas of breast tissues from BRCA1, BRCA2 mutation carriers and compared this single-cell atlas of mutation carriers with our previously described single-cell breast atlas of healthy non-carriers. We observed that BRCA1 but not BRCA2 mutations altered the ratio between basal (basal-myoepithelial), luminal progenitor (luminal adaptive secretory precursor, LASP), and mature luminal (luminal hormone sensing) cells in breast tissues. A unique subcluster of cells within LASP cells is underrepresented in case of BRCA1 and BRCA2 mutation carriers compared with non-carriers. Both BRCA1 and BRCA2 mutations specifically altered transcriptomes in epithelial cells which are an integral part of NFκB, LARP1, and MYC signaling. Signaling pathway alterations in epithelial cells unique to BRCA1 mutations included STAT3, BRD4, SMARCA4, HIF2A/EPAS1, and Inhibin A signaling. BRCA2 mutations were associated with upregulation of IL6, PDK1, FOXO3, and TNFSF11 signaling. These signaling pathway alterations are sufficient to alter sensitivity of BRCA1/BRCA2-mutant breast epithelial cells to transformation as epithelial cells from BRCA1 mutation carriers overexpressing hTERT + PIK3CA H1047R generated adenocarcinomas, whereas similarly modified mutant BRCA2 cells generated basal carcinomas in NSG mice. Thus, our studies provide a high-resolution transcriptome atlas of breast epithelial cells of BRCA1 and BRCA2 mutation carriers and reveal their susceptibility to PIK3CA mutation-driven transformation. Significance: This study provides a single-cell atlas of breast tissues of BRCA1/2 mutation carriers and demonstrates that aberrant signaling due to BRCA1/2 mutations is sufficient to initiate breast cancer by mutant PIK3CA.

Year:

2024

Single-cell transcriptomics studies have begun to identify breast epithelial cell and stromal cell specific transcriptome differences between BRCA1/2 mutation carriers and non-carriers. We generated a single-cell transcriptome atlas of breast tissues from BRCA1, BRCA2 mutation carriers and compared this single-cell atlas of mutation carriers with our previously described single-cell breast atlas of healthy non-carriers. We observed that BRCA1 but not BRCA2 mutations altered the ratio between basal (basal-myoepithelial), luminal progenitor (luminal adaptive secretory precursor, LASP), and mature luminal (luminal hormone sensing) cells in breast tissues. A unique subcluster of cells within LASP cells is underrepresented in case of BRCA1 and BRCA2 mutation carriers compared with non-carriers. Both BRCA1 and BRCA2 mutations specifically altered transcriptomes in epithelial cells which are an integral part of NFκB, LARP1, and MYC signaling. Signaling pathway alterations in epithelial cells unique to BRCA1 mutations included STAT3, BRD4, SMARCA4, HIF2A/EPAS1, and Inhibin A signaling. BRCA2 mutations were associated with upregulation of IL6, PDK1, FOXO3, and TNFSF11 signaling. These signaling pathway alterations are sufficient to alter sensitivity of BRCA1/BRCA2-mutant breast epithelial cells to transformation as epithelial cells from BRCA1 mutation carriers overexpressing hTERT + PIK3CA H1047R generated adenocarcinomas, whereas similarly modified mutant BRCA2 cells generated basal carcinomas in NSG mice. Thus, our studies provide a high-resolution transcriptome atlas of breast epithelial cells of BRCA1 and BRCA2 mutation carriers and reveal their susceptibility to PIK3CA mutation-driven transformation. Significance: This study provides a single-cell atlas of breast tissues of BRCA1/2 mutation carriers and demonstrates that aberrant signaling due to BRCA1/2 mutations is sufficient to initiate breast cancer by mutant PIK3CA.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (18)

Sarah Tasian

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Peng Gao

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Yuan Luo

Chief AI Officer and Associate Professor

Northwestern University

UNITED STATES
View details

Maxim Frolov

University of Chicago

UNITED STATES
View details

Mignon L. Loh

Professor

University of Washington

UNITED STATES
View details

Curtis W. McCloskey

Assistant Professor

UPMC Hillman Cancer Center

UNITED STATES
View details

Rama Khokha

Professor

University of Toronto

CANADA
View details

Elliot Stieglitz

Associate Professor

UCSF Benioff Children's Hospital

UNITED STATES
View details

Elizaveta V Benevolenskaya

Professor

University of Illinois Chicago (UIC)

UNITED STATES
View details

Kevin Shannon

University of California

UNITED STATES
View details

Steven Angus

Assistant Professor

Indiana State University

UNITED STATES
View details

Seema Khan

Professor

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Harikrishna Nakshatri

Professor

Indiana State University

UNITED STATES
View details

Marcelo Bonini

Senior Member & Chair

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Yunlong Liu

Professor

Indiana State University

UNITED STATES
View details

George Sandusky

Professor

Indiana University-Purdue University Indianapolis

UNITED STATES
View details

Scott C. Kogan

University of California, San Francisco

UNITED STATES
View details

Maria Paula Zappia

Research Assistant Professor

University of Chicago

UNITED STATES
View details